A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Advancing Healthcare Energy: Olympus Awarded PROVISTA Contract


Olympus announced today that it has been awarded a contract for its advanced energy portfolio by Provista Inc. This new, nationwide agreement provides Provista members with negotiated pricing for Olympus® energy products, including the POWERSEAL™ sealer/divider, the SONICBEAT™ ultrasonic portfolio and THUNDERBEAT™ hybrid energy portfolio.

The multi-year agreement was effective as of July 1, 2023.

The Olympus advanced energy portfolio is available under this contract, including:

  • The Universal Surgical Energy Generator (EPF-1), which provides common forms of surgical energy and eliminates the need for multiple generators.
  • The SONICBEAT Ultrasonic Energy Portfolio, which offers precise dissection with 5mm sealing and secure tissue grasping thanks to unique wiper jaw design.1
  • The THUNDERBEAT Hybrid Energy Portfolio, which offers efficiency through fast cutting and versatility and 7mm sealing and precise dissection.2
  • The POWERSEAL Sealer/Divider, which features a curved, tapered and double-action Maryland dissector/grasper design and vessel sealing up to and including 7mm, including pulmonary vessels, tissue bundles and lymphatics.3

Jay Sullivan, Group Vice President, Enterprise Solutions, Medical Systems Group, Olympus

“Contract awards are important to our business. But even more important is that the Provista awards create opportunities for customers such as ASCs to access state-of-the-art equipment toward improving patient care in a value-based framework. The ASC market is important for healthcare providers and the communities they serve, and we are focused on growing our presence there.”

Energy Options Offered Through Olympus

Olympus offers an array of energy options such as the THUNDERBEAT hybrid energy devices portfolio that deliver ultrasonic and bipolar energy simultaneously for tissue management, including hemostatic cutting and dissection, in laparoscopic surgery and open surgery. Olympus’ POWERSEAL devices can be used in general surgery and gynecological, colorectal, bariatric, urological, thoracic and vascular surgical procedures.

EPF-1 Generator

The EPF-1 generator, with its accessories and ancillary equipment, is intended for cutting and coagulation of tissue in open, laparoscopic and endoscopic surgery and should only be used by a qualified physician in an adequate medical environment.  Improper use or use of incompatible equipment with these generators may lead to excessive or incorrect HF and cause thermal or other injuries for the patient and/or operator.

All plugs must be securely inserted into the corresponding sockets for proper use. Be aware that if the main plug is accidentally disconnected during a procedure, the electrosurgical generator immediately turns off and this may result in complications for the patient should it occur during energy delivery. Please refer to the instructions for use prior to usage.


1 Data on file with Olympus (869-2368, 869-2512)
2 Data on file with Olympus (868-4375, 868-4378, 868-3710)
3 Data on file with Olympus (DN004705, DN0044706)

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy